Related Experiment Video

Updated: Aug 15, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology

Scott C Vermilyea1,2, Marina E Emborg1,2,3

  • 11 Neuroscience Training Program, University of Wisconsin , Madison, Wisconsin.

Stem Cells and Development
|February 7, 2018
PubMed

Insights

The LRRK2 G2019S mutation is a common cause of Parkinson's disease. Patient-derived cells and in vitro models are crucial for understanding disease mechanisms and developing new therapies.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • The Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most frequent genetic factor in Parkinson's disease (PD), affecting up to 40% in North African Arab populations.
  • This mutation exhibits high penetrance, with 80% of carriers developing PD by age 70.

Purpose of the Study:

  • To critically review the role of in vitro modeling in understanding LRRK2 G2019S-related Parkinson's disease.
  • To analyze the utility of patient-derived cell lines in identifying and validating therapeutic targets for PD.

Main Methods:

  • Utilizing induced pluripotent stem cells (iPSCs) derived from patient fibroblasts to generate dopaminergic neurons.
  • Studying G2019S-related pathology, including mitochondrial dysregulation, reactive oxygen species, neurite abnormalities, and cell death.

Main Results:

  • In vitro models have elucidated LRRK2-related mechanisms contributing to Parkinson's disease pathology.
  • The G2019S mutation is hypothesized to increase the catalytic rate of LRRK2, leading to cellular dysfunction.

Conclusions:

  • Patient-derived cell lines are essential for a 3R approach in translational research and personalized medicine for Parkinson's disease.
  • In vitro modeling significantly contributes to the current knowledge of LRRK2 G2019S and therapeutic target validation.
Keywords:
LRRK2 G2019SParkinson's diseasekinase inhibitorspatient-derived cells

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...